MDRNA Advances RNAi Pipeline with Selection of Lead Candidate for Hypercholesterolemia Program
News Oct 08, 2008
MDRNA, Inc. has announced that it has advanced its RNAi pipeline with the selection of a Lead Candidate in its hypercholesterolemia program targeting Apolipoprotein B (ApoB).
The compound, designated MDR-04227, was developed using MDRNA's propriety drug discovery engine, which is built on a broad and enabling intellectual property estate and an in-house novel and proprietary delivery technology.
"We continue to execute on our plan to advance our therapeutic programs toward human clinical development," stated J. Michael French, President and CEO of MDRNA, Inc.
"The selection of a Lead Candidate in our hypercholesterolemia program reflects the strength of our drug discovery engine, specifically the rapid advances we've made in siRNA delivery. Further, I believe the speed and efficiency by which we can develop a lead candidate demonstrates our ability to utilize this drug discovery platform to support a broad therapeutic collaboration with a pharmaceutical partner. MDRNA's unique combination of technology, in-house capability and intellectual property portfolio permits us to broadly support a potential partner's needs and develop siRNAs directed against any human gene target."
MDR-04227 is a Dicer substrate siRNA formulated with a proprietary lipid-based delivery formulation derived from the Company's DiLA2 Platform.
In a preclinical animal model of hypercholesterolemia, MDR-04227 was shown to be potent with an IC50 of less than 100 pM. When formulated for systemic administration using DiLA2, MDR-04227 demonstrated approximately 85% knockdown in target messenger RNA of ApoB and a similar level of reduction of serum cholesterol following a single 1 mg/kg dose of siRNA. The Company has filed numerous patent applications relating to this siRNA construct and delivery formulation.
Genetic Discovery Helps Determine the Difference Between Aggressive & Benign Bone TumorsNews
The first genetic marker for the bone tumor, osteoblastoma, has been discovered. Whole-genome and transcriptome sequencing of human bone tumors revealed that a genetic change that affects the transcription factor, FOS, is a hallmark mutation of osteoblastoma. The results will help clinicians correctly distinguish benign osteoblastoma tumors from aggressive osteosarcoma tumors and direct the correct treatment.READ MORE